GE HealthCare Technologies Inc.

GEHC · NASDAQ · USD

Can GE HealthCare turn a record backlog and its biggest product launch cycle in a decade into faster growth and margin recovery while fixing Patient Care Solutions and absorbing cost inflation?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Order book and backlog

    Orders are growing faster than sales across imaging, ultrasound and radiopharmaceuticals, so growth depends on backlog conversion rather than on demand.

  • New product cycle

    Newly cleared imaging and ultrasound products carry higher prices and lower manufacturing cost, which should lift both growth and gross margin as they scale.

  • Contrast media supply

    Contrast media demand is running close to industry supply, giving the pharmaceutical diagnostics business volume and pricing support even as new generic competitors appear.

  • Cost offsets and cash

    Price and cost actions are intended to cover most of the input-cost inflation, and the business still converts a large share of profit into free cash flow.

Bear case

  • Input cost inflation

    Inflation in memory chips, oil and freight forced a cut to profit guidance, and the price and cost offsets arrive with a lag over the following quarters.

  • Patient Care Solutions drag

    The patient monitoring and anesthesia business is shrinking, losing money and short of components, and management is now reviewing whether to keep it at all.

  • China market weakness

    China is still guided to decline as volume-based procurement expands, so the company's growth plan does not depend on any recovery in that market.

  • New products arrive late

    Most new imaging products only reach revenue in 2027 because of approval, room build and installation cycles, so near-term growth rests on the existing portfolio.

Bull and bear points

Growth & Execution

In short: Orders and backlog are at records, but the patient monitoring and anesthesia business keeps shrinking.

Bull · 2

  • Orders grew 11% and book-to-bill reached 1.15x

    Bookings are running well ahead of sales, and management attributes the growth to broad demand across imaging, ultrasound and radiopharmaceuticals rather than to any single large order.

    Q2 FY2026 call

  • Flyrcado weekly doses rose about 40% since April

    Management previously said it would go slow on the launch until supply was reliable; it now reports 545 doses a week, more customers and steadier suppliers, and repeats the 2028 revenue target.

    Tone shiftQ4 FY2025 → Q2 FY2026
Bear · 2

  • Patient Care Solutions is now under strategic review

    Management previously described cost actions as enough to restore this segment's profitability; it now says a review is underway that includes continued ownership or a sale, after the segment posted a negative operating profit.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Key imaging launches contribute mainly in 2027

    European clearance for the photon-counting CT system slipped, and since orders need approval, room builds and installation, the new imaging cycle adds little to 2026 revenue and grows more in 2027.

    Q2 FY2026 call

Profitability & Financial Strength

In short: Margins expanded outside Patient Care Solutions, but input-cost inflation has forced a lower profit outlook.

Bull · 2

  • Margin rose about 100 basis points excluding PCS

    Even through the steepest quarterly input-cost inflation in years, price and cost actions kept the rest of the portfolio expanding margin, and management expects that carry-through into 2027.

    Q2 FY2026 call

  • Free cash flow holds near $1.6 billion

    Cash generation of 7.8% of revenue funded the Intelerad acquisition, share repurchases and the dividend, which is why management can keep investing in new products while returning cash.

    Filed financials
Bear · 2

  • Full-year profit guidance was cut in April

    In February management guided to $4.95 to $5.15 of adjusted EPS and 15.8% to 16.1% margin; in April it cut both on roughly $250 million of new input costs and has not raised the range since.

    Tone shiftQ4 FY2025 → Q1 FY2026

  • Net debt rose to $8.0 billion from $6.5 billion

    The Intelerad acquisition and buybacks were largely debt funded, so a larger share of cash flow now goes to interest while component and freight costs are still elevated.

    Filed financials

Market Position

In short: Contrast supply is tight and imaging is differentiated, but generics and China procurement pressure pricing.

Bull · 2

  • Contrast media demand is close to outpacing supply

    Management expects contrast volumes to keep growing with procedures and says it wins on supply reliability and the breadth of product sizes hospitals need, which supports price as well as volume.

    Q2 FY2026 call

  • AI features support higher prices and service capture

    Products such as Vivid Pioneer carry embedded AI that customers pay more for and that pull through service contracts, so the portfolio earns both a better price and a larger recurring revenue base.

    Q2 FY2026 call
Bear · 2

  • A generic competitor has entered the contrast market

    Contrast media is the largest part of pharmaceutical diagnostics, and because injectable contrast can be substituted at the pharmacy level, an approved generic can take volume even where price holds.

    Q2 FY2026 call

  • Chinese procurement rules keep pushing prices down

    Management expects more Chinese hospital tenders to move to volume-based purchasing, which lowers selling prices; it has added provincial government affairs staff but still plans for lower China sales.

    Q2 FY2026 call